Cite
ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity.
MLA
Wang, Qi, et al. “ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity.” Journal of Immunology Research, Sept. 2022, pp. 1–16. EBSCOhost, https://doi.org/10.1155/2022/6863240.
APA
Wang, Q., Cao, T., Zhang, X., Hui, J., Wang, C., Zhang, W., Wang, P., Zhou, Y., & Han, S. (2022). ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity. Journal of Immunology Research, 1–16. https://doi.org/10.1155/2022/6863240
Chicago
Wang, Qi, Tianyu Cao, Xiaohui Zhang, Juan Hui, Chen Wang, Wenyao Zhang, Pei Wang, Yun Zhou, and Shuang Han. 2022. “ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity.” Journal of Immunology Research, September, 1–16. doi:10.1155/2022/6863240.